<DOC>
	<DOC>NCT01480648</DOC>
	<brief_summary>This first-in-man trial forms the basis for potential clinical development of BI 144807 in the indications of asthma and allergic rhinitis. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising doses of BI 144807 will be assessed in healthy male volunteers.</brief_summary>
	<brief_title>Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: 1. healthy male subjects Exclusion criteria: 1. any relevant deviation from healthy conditions</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>